肝脏 ›› 2026, Vol. 31 ›› Issue (9): 1310-1313.

• 肝癌 • 上一篇    下一篇

AFP、AFP-L3%与PIVKA-Ⅱ联合检测评估肝细胞癌疗效及预后

王翔, 居承辉, 王根   

  1. 211300 南京 南京市高淳人民医院医学检验科(王翔,居承辉);
    210016 南京 东部战区总医院,国家肾脏疾病临床医学研究中心(王根)
  • 收稿日期:2026-02-10 出版日期:2026-09-30 发布日期:2026-11-16

Value of combined detection of AFP, AFP-L3%, and PIVKA-Ⅱ in therapeutic monitoring and prognostic assessment of hepatocellular carcinoma

Wang Xiang1, Ju Chenghui1, Wang Gen2   

  1. 1. Department of Laboratory Medicine, Gaochun People's Hospital, Nanjing 211300, China;
    2. National Clinical Research Center for Kidney Disease, General Hospital of Eastern Theater Command, PLA, Nanjing 210016, China
  • Received:2026-02-10 Online:2026-09-30 Published:2026-11-16

摘要: 目的 探讨甲胎蛋白(AFP)、甲胎蛋白异质体3比率(AFP-L3%)及脱-γ-羧基凝血酶原(PIVKA-Ⅱ)联合检测对肝细胞癌疗效及预后的评估价值。方法 纳入2022年1月至2024年2月南京市高淳人民医院诊治的肝细胞癌患者98例。于治疗前及治疗后检测血清AFP、AFP-L3%和PIVKA-Ⅱ水平,并完成影像学随访。依据改良实体瘤疗效评价标准(mRECIST)将患者分为完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)和疾病进展(PD)组。比较不同疗效组患者肿瘤标志物的基线水平及治疗前后变化情况,采用ROC曲线分析各指标变化率对疾病进展的预测效能,并进一步评估联合检测与无进展生存期(PFS)及1年总生存率(OS)的关系。结果 不同mRECIST疗效分组患者AFP、AFP-L3%及PIVKA-Ⅱ基线水平差异均存在显著统计学意义(均P<0.05),随着疗效由CR、PR向SD、PD转变,上述指标水平呈升高趋势。治疗后,CR、PR组AFP下降率分别为82.6(71.4,92.3)%和64.8(48.2,78.9)%,明显高于SD组的23.4(8.7,39.6)%和PD组的-12.6(-38.4,5.9)%(P<0.05);AFP-L3%下降率分别为71.3(56.8,85.1)%、52.6(36.4,69.8)%、18.9(6.4,32.5)%和-6.7(-21.3,8.4)%(P<0.05);PIVKA-Ⅱ下降率分别为79.4(62.1,88.6)%、61.7(45.8,75.3)%、21.6(7.9,35.4)%和-15.8(-41.7,3.6)%(P<0.05)。ROC 曲线分析显示,AFP、AFP-L3%及PIVKA-Ⅱ变化率预测疾病进展的AUC分别为0.74(95%CI:0.64~0.84)、0.77(95%CI:0.68~0.86)和0.80(95%CI:0.71~0.89),3项指标联合检测AUC为0.89(95%CI:0.82~0.96)。预后分析显示,AFP、AFP-L3%及PIVKA-Ⅱ均下降患者的PFS为18.4(12.6,25.8)个月,明显长于任意2项下降11.2(7.4,16.3)个月和≤1项下降6.3(3.1,9.8)个月(P<0.05),其1年OS率分别为85.0%、63.8%和38.7%(P<0.05)。结论 AFP、AFP-L3%与PIVKA-Ⅱ在肝细胞癌治疗过程中呈现出与影像学疗效一致的动态变化特征,3者联合检测在疗效监测、疾病进展预测及预后评估方面具有较高的临床应用价值,可作为影像学评估的有益补充。

关键词: 肝细胞癌, AFP, AFP-L3%, PIVKA-Ⅱ

Abstract: Objective To investigate the clinical value of combined detection of alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3%), and protein induced by vitamin K absence or antagonist-Ⅱ (PIVKA-Ⅱ) in monitoring therapeutic response and evaluating prognosis in patients with hepatocellular carcinoma (HCC). Methods A total of 98 patients with HCC from Gaochun People's Hospital were enrolled. Serum levels of AFP, AFP-L3%, and PIVKA-Ⅱ were measured before and after treatment, and all patients underwent imaging follow-up. According to the modified Response Evaluation Criteria in Solid Tumors (mRECIST), patients were classified into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) groups. Baseline levels and dynamic changes of tumor biomarkers were compared among different response groups. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive value of biomarker change rates for disease progression, and the associations between combined biomarker detection and progression-free survival (PFS) as well as 1-year overall survival (OS) were further analyzed. Results Significant differences in baseline levels of AFP, AFP-L3%, and PIVKA-Ⅱ were observed among patients with different mRECIST response categories (all P<0.05), and the levels showed a gradual increasing trend as therapeutic response worsened from CR and PR to SD and PD. After treatment, the decline rates of AFP in the CR and PR groups were 82.6% (71.4%, 92.3%) and 64.8% (48.2%, 78.9%), respectively, which were significantly higher than those in the SD group [23.4% (8.7%, 39.6%)] and the PD group [-12.6% (-38.4%, 5.9%)] (P<0.05). The decline rates of AFP-L3% were 71.3% (56.8%, 85.1%), 52.6% (36.4%, 69.8%), 18.9% (6.4%, 32.5%), and -6.7% (-21.3%, 8.4%) in the CR, PR, SD, and PD groups, respectively (P<0.05). The decline rates of PIVKA-Ⅱ were 79.4% (62.1%, 88.6%), 61.7% (45.8%, 75.3%), 21.6% (7.9%, 35.4%), and -15.8% (-41.7%, 3.6%) in the four groups, respectively (P<0.05). ROC curve analysis showed that the AUC values of AFP, AFP-L3%, and PIVKA-Ⅱ change rates for predicting disease progression were 0.74 (95% CI: 0.64~0.84), 0.77 (95% CI: 0.68~0.86), and 0.80 (95% CI: 0.71~0.89), respectively, while the combined detection of the three indicators yielded an AUC of 0.89 (95% CI: 0.82~0.96). Prognostic analysis revealed that patients with concurrent decreases in AFP, AFP-L3%, and PIVKA-Ⅱ had a median PFS of 18.4 (12.6, 25.8) months, which was significantly longer than that in patients with decreases in any two markers [11.2 (7.4, 16.3) months] and those with a decrease in ≤1 marker [6.3 (3.1, 9.8) months] (P<0.05). The corresponding 1-year OS rates were 85.0%, 63.8%, and 38.7%, respectively (P<0.05). Conclusion AFP, AFP-L3% and PIVKA-Ⅱ exhibit dynamic changes consistent with imaging-based therapeutic response during the treatment of hepatocellular carcinoma. Combined detection of these biomarkers provides substantial clinical value in therapeutic monitoring, prediction of disease progression, and prognostic assessment, and may serve as a useful complement to imaging evaluation.

Key words: Hepatocellular carcinoma, Alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein, Protein induced by vitamin K absence or antagonist-Ⅱ